Alpha Crest Capital Management LLC Anavex Life Sciences Corp. Transaction History

Alpha Crest Capital Management LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$8.9 - $12.86 $148,914 - $215,173	-16,732 Reduced 36.59%	28,994 $299,000
Q2 2022 Aug 11, 2022	BUY	$7.31 - $12.84 $32,229 - $56,611	4,409 Added 10.67%	45,726 $458,000
Q1 2022 May 12, 2022	BUY	$9.74 - $17.69 $275,895 - $501,086	28,326 Added 218.04%	41,317 $509,000
Q4 2021 Feb 09, 2022	SELL	$16.88 - $23.31 $23,783 - $32,843	-1,409 Reduced 9.78%	12,991 $225,000
Q3 2021 Nov 10, 2021	BUY	$16.82 - $25.75 $242,208 - $370,800	14,400 New	14,400 $258,000

155

27.3M

515K

838K

Ticker AVXL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,942,800
Market Cap $673M
Description
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patien...

Get notified when there are updates to the investment portfolio of Alpha Crest Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Alpha Crest Capital Management LLC with notifications on news.